From a therapeutic standpoint, these findings highlight the potential of RPL41 as a dual-functional candidate for RB treatment: it can serve as a targeted agent to suppress the ATF4-driven oncogenic pathway and act as a chemosensitizer to enhance the efficacy of current platinum-based therapeutic regimens. The gene discussed is ATF4; the disease is retinoblastoma.